|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
127,470,000 |
Market
Cap: |
1.82(B) |
Last
Volume: |
519,454 |
Avg
Vol: |
1,077,986 |
52
Week Range: |
$11.665 - $20.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,161 |
9,748 |
12,417 |
12,417 |
Total Sell Value |
$114,090 |
$152,803 |
$201,886 |
$201,886 |
Total People Sold |
2 |
2 |
2 |
2 |
Total Sell Transactions |
2 |
3 |
4 |
4 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dent Michael T |
Director |
|
2013-03-05 |
4 |
S |
$3.00 |
$900,000 |
I/I |
(300,000) |
1,228,050 |
|
- |
|
Albitar Maher |
Chief Medical OfficerOfficer |
|
2013-02-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,000 |
|
- |
|
Albitar Maher |
Chief Medical OfficerOfficer |
|
2013-02-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
34,000 |
|
- |
|
Hipp Raymond R |
Director |
|
2012-12-20 |
4 |
A |
$2.75 |
$518,570 |
D/D |
188,571 |
235,714 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-12-20 |
4 |
GD |
$2.75 |
$62,260 |
D/D |
22,640 |
346,615 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-12-20 |
4 |
D |
$2.75 |
$10,047,716 |
I/I |
(3,653,715) |
3,712,969 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-12-20 |
4 |
S |
$2.75 |
$3,025 |
I/I |
(1,100) |
7,366,684 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-12-19 |
4 |
S |
$2.75 |
$22,619 |
I/I |
(8,225) |
7,367,784 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-12-18 |
4 |
S |
$2.75 |
$1,738,314 |
I/I |
(632,114) |
7,376,009 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-09-28 |
4 |
S |
$3.01 |
$107,798 |
D/D |
(35,800) |
369,255 |
|
- |
|
Dent Michael T |
Director |
|
2012-09-28 |
4 |
S |
$3.01 |
$225,750 |
I/I |
(75,000) |
1,528,050 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-09-26 |
4 |
S |
$3.05 |
$76,250 |
D/D |
(25,000) |
405,055 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2012-09-26 |
4 |
S |
$3.03 |
$9,573 |
D/D |
(3,155) |
0 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2012-07-27 |
4 |
D |
$2.00 |
$10,000 |
D/D |
(5,000) |
3,155 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2012-07-26 |
4 |
D |
$1.97 |
$9,850 |
D/D |
(5,000) |
8,155 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2012-06-20 |
4 |
D |
$1.70 |
$51,000 |
I/I |
(30,000) |
8,008,123 |
|
- |
|
Clearman Stephen J |
10% Owner |
|
2012-06-20 |
4 |
B |
$1.70 |
$114,575 |
D/D |
67,437 |
4,848,334 |
2.45 |
- |
|
Clearman Stephen J |
10% Owner |
|
2012-06-19 |
4 |
B |
$1.65 |
$8,250 |
D/D |
5,000 |
4,780,897 |
2.37 |
- |
|
Clearman Stephen J |
10% Owner |
|
2012-06-18 |
4 |
B |
$1.64 |
$19,034 |
D/D |
11,600 |
4,775,897 |
2.37 |
- |
|
Dent Michael T |
Director |
|
2012-06-07 |
4 |
A |
$1.50 |
$15,750 |
D/D |
10,500 |
34,500 |
|
- |
|
Jones Steven C |
Executive VP of Finance |
|
2012-06-06 |
4 |
A |
$1.50 |
$150,000 |
I/I |
100,000 |
190,000 |
|
- |
|
Jones Steven C |
Executive VP of Finance |
|
2012-06-06 |
4 |
A |
$1.50 |
$39,377 |
D/D |
26,251 |
430,055 |
|
- |
|
Peterson Peter M |
Director |
|
2012-06-05 |
4 |
A |
$1.50 |
$15,750 |
D/D |
10,500 |
34,500 |
|
- |
|
Robison William J |
Director |
|
2012-06-04 |
4 |
A |
$1.50 |
$112,500 |
D/D |
75,000 |
144,713 |
|
- |
|
Clearman Stephen J |
10% Owner |
|
2012-05-17 |
4 |
B |
$1.70 |
$169,980 |
D/D |
100,000 |
4,764,297 |
2.45 |
- |
|
544 Records found
|
|
Page 20 of 22 |
|
|